✦ LIBER ✦

Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV

✍ Scribed by Paul Pollack; Jessie R. Groothuis; G.M. Barbarotto

Publisher: Springer
Year: 2002
Tongue: English
Weight: 62 KB
Volume: 8
Category: Article
ISSN: 1341-321X
DOI: 10.1007/s10156-002-0178-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Using agent- and organisation-oriented p

Using agent- and organisation-oriented programming to develop a team of agents for a competitive game

✍ Jomi F. Hübner; Rafael H. Bordini 📂 Article 📅 2010 🏛 Springer Netherlands 🌐 English ⚖ 807 KB

Development of a low VOC chemical agent

Development of a low VOC chemical agent resistant coating for use with supercritical CO2

✍ Anna Wojciechowski; Jeff Lewis; Tom Braswell 📂 Article 📅 1998 🏛 John Wiley and Sons ⚖ 727 KB

Pharmaceutical development of a lyophili

Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent

✍ Monique W.J. Den Brok; Bastiaan Nuijen; Christiane Lutz; Hans-Georg Opitz; Jos H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

Imexon is a member of the class of 2-cyanoaziridine derivatives, which have been of interest as immunomodulators and anticancer agents since the late 1970s. For the scheduled phase I clinical trials a stable, sterile, injectable pharmaceutical dosage form containing 100 mg Imexon was required. Despi

A capillary electrophoresis chip for the

A capillary electrophoresis chip for the analysis of print and film photographic developing agents in commercial processing solutions using indirect fluorescence detection

✍ Somsak Sirichai; Andrew J. de Mello 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views